MEGAN CHAISSON: Open Payments
NPI 1649850124 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,666 in 59 payments from 14 companies in 2025. Trend: 2023 $519 · 2024 $1,312 · 2025 $1,666
Food & beverage: $1,666
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $225 |
| Neurocrine BioSciences, Inc. | 5 | $211 |
| Janssen Pharmaceuticals, Inc | 3 | $177 |
| Otsuka America Pharmaceutical, Inc. | 4 | $161 |
| E.R. Squibb & Sons, L.L.C. | 11 | $149 |
| Alkermes, Inc. | 4 | $130 |
| Merck Sharp & Dohme LLC | 6 | $129 |
| Teva Pharmaceuticals USA, Inc. | 2 | $124 |
| Axsome Therapeutics, Inc. | 2 | $117 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $113 |
Products named: VRAYLAR, INGREZZA, SPRAVATO, COBENFY, REXULTI, ARISTADA, PIFELTRO, Auvelity.
Industry payments across LA — which companies pay providers there.
